Every material Form 8-K CVS Health filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CVS Health reported third quarter 2025 total revenues of $102.9 billion, up 7.8%, and a GAAP diluted loss of $3.13 per share, compared with earnings of $0.07 per share a year earlier. The loss reflects a $5.7 billion goodwill impairment charge on its Health Care Delivery unit, while adjusted EPS rose to $1.60 from $1.09. The company cut its full-year GAAP EPS guidance to a loss but raised its adjusted EPS guidance, a split that shareholders will need to weigh.
Total revenues rose to $102.9 billion from $95.4 billion, a 7.8% increase
GAAP diluted loss of $3.13 per share included a $5.7 billion goodwill impairment; a $483 million deconsolidation gain partly offset it
Adjusted EPS of $1.60 compared with $1.09 a year earlier, driven by the Health Care Benefits segment
Full-year GAAP diluted EPS guidance cut to $(0.34) to $(0.24) from $3.84 to $3.94; adjusted EPS guidance raised to $6.55 to $6.65 from $6.30 to $6.40
CVS Health reported second-quarter 2025 revenue of $98.9 billion, up 8.4%, but GAAP diluted EPS fell to $0.80 from $1.41 after $833 million in litigation charges. The company raised its full-year adjusted EPS guidance to $6.30 to $6.40 while cutting its GAAP EPS guidance to $3.84 to $3.94, so shareholders face a mixed picture of stronger underlying performance and lower reported profit.
Q2 total revenues were $98.9 billion, up from $91.2 billion a year earlier; adjusted EPS was $1.81 versus $1.83
GAAP diluted EPS guidance was revised to $3.84 to $3.94 from $4.23 to $4.43
Adjusted EPS guidance was raised to $6.30 to $6.40 from $6.00 to $6.20
Cash flow from operations guidance was raised to at least $7.5 billion from about $7.0 billion
CVS Health reported first-quarter 2025 results with total revenues up 7.0% to $94.6 billion and GAAP diluted EPS of $1.41, up from $0.88 a year earlier. The company raised its full-year Adjusted EPS and cash flow from operations guidance but lowered its full-year GAAP diluted EPS guidance, and it said it will exit the individual exchange business, so shareholders face a mixed picture of higher adjusted profit expectations alongside lower GAAP expectations.
Total revenues rose 7.0% to $94.6 billion; GAAP diluted EPS was $1.41 versus $0.88, and Adjusted EPS was $2.25 versus $1.31.
2025 Adjusted EPS guidance raised to $6.00 to $6.20 from $5.75 to $6.00; GAAP diluted EPS guidance revised to $4.23 to $4.43 from $4.58 to $4.83.
Quarter included a $387 million Omnicare litigation charge tied to an April 2025 jury verdict and a $247 million pre-tax loss on the Accountable Care asset wind-down and sale.
Full-year cash flow from operations guidance raised to approximately $7.0 billion from approximately $6.5 billion; the company will exit the individual exchange business where Aetna independently operates ACA plans for 2026.
CVS Health appointed Brian O. Newman, former CFO of United Parcel Service, as executive vice president and chief financial officer effective May 12, 2025, replacing Thomas F. Cowhey, who becomes a strategic advisor to the CEO. The company also named Amy L. Compton-Phillips, M.D. as chief medical officer effective May 19, 2025. The filing also says the company currently expects 2025 results to meet or exceed prior guidance, based on year-to-date results through February, while first-quarter closing procedures are not yet complete.
Brian O. Newman becomes CFO effective May 12, 2025, and is CFO designate from April 21, 2025; he will receive a $1.0 million annualized base salary and a $7.0 million target annual equity award
Thomas F. Cowhey ceases to be CFO on May 12, 2025, and will remain as Strategic Advisor to the President and CEO until a departure date not yet determined
Amy L. Compton-Phillips, M.D. becomes executive vice president and chief medical officer effective May 19, 2025
Company expects 2025 financial results will meet or exceed previously issued guidance, but first-quarter 2025 financial closing is not yet complete and results may change
CVS Health reported fourth-quarter and full-year 2024 results on February 12, 2025, with revenue up 4.2% in both periods but profit down sharply. The company also issued 2025 guidance of $5.75 to $6.00 in adjusted EPS and $4.58 to $4.83 in GAAP diluted EPS, which shareholders will weigh against the lower 2024 earnings.
Q4 2024 total revenues rose to $97.7 billion, up 4.2%, while adjusted EPS fell to $1.19 from $2.12 a year earlier.
The Health Care Benefits segment posted a Q4 adjusted operating loss of $439 million, compared with adjusted operating income of $676 million, citing higher utilization and Medicare Advantage star ratings.
Full-year 2024 GAAP diluted EPS was $3.66 versus $6.47, and adjusted EPS was $5.42 versus $8.74.
2025 guidance: adjusted EPS of $5.75 to $6.00, GAAP diluted EPS of $4.58 to $4.83, and cash flow from operations of approximately $6.5 billion.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CVS Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →